DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Tudorza Pressair (Aclidinium Bromide) - Summary



TUDORZA PRESSAIR consists of a dry powder formulation of aclidinium bromide for oral inhalation only. Aclidinium bromide, the active component of TUDORZA PRESSAIR is an anticholinergic with specificity for muscarinic receptors.

TUDORZA™ PRESSAIR™ (aclidinium bromide inhalation powder) is indicated for the long-term, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

See all Tudorza Pressair indications & dosage >>


Published Studies Related to Tudorza Pressair (Aclidinium Bromide)

Activity of aclidinium bromide, a new long-acting muscarinic antagonist: a phase I study. [2010]
ability to reduce methacholine-induced bronchoconstriction... CONCLUSION: Aclidinium produced statistically significant and sustained

Bronchodilatory effects of aclidinium bromide, a long-acting muscarinic antagonist, in COPD patients. [2010]
doses of aclidinium bromide in patients with COPD... CONCLUSION: Aclidinium bromide 100-900microg produced sustained bronchodilation

Aclidinium bromide for the treatment of chronic obstructive pulmonary disease. [2014]
CONCLUSION: Aclidinium bromide is an inhaled anticholinergic that improves lung

Safety and pharmacokinetics of single doses of aclidinium bromide, a novel long-acting, inhaled antimuscarinic, in healthy subjects. [2009]
tolerability, safety and pharmacokinetics of aclidinium in healthy subjects... CONCLUSIONS: Aclidinium appears to be safe and well tolerated in single doses of

more studies >>

Page last updated: 2014-12-01

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017